ES2153862T3 - Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas. - Google Patents

Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.

Info

Publication number
ES2153862T3
ES2153862T3 ES94929116T ES94929116T ES2153862T3 ES 2153862 T3 ES2153862 T3 ES 2153862T3 ES 94929116 T ES94929116 T ES 94929116T ES 94929116 T ES94929116 T ES 94929116T ES 2153862 T3 ES2153862 T3 ES 2153862T3
Authority
ES
Spain
Prior art keywords
parenteral administration
malignal
bisulfan
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929116T
Other languages
English (en)
Inventor
Borje S Andersson
Harshal P Bhagwatwar
Diana Shu-Lian Chow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Houston
University of Texas System
Original Assignee
University of Houston
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22442547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2153862(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Houston, University of Texas System filed Critical University of Houston
Application granted granted Critical
Publication of ES2153862T3 publication Critical patent/ES2153862T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTAN FORMULACIONES PARENTERALES ESTABLES DE BISULFAN SEGURAS PARA SU ADMINISTRACION PARENTERAL. SE HA DESARROLLADO UNA PRUEBA DE HPLC PARA LA DETECCION DEL BISULFAN CAPAZ DE CUANTIFICAR LAS CONCENTRACIONES EN PLASMA TAN BAJAS COMO APROXIMADAMENTE 100 NG/ML. LA ESTABILIDAD DE ESTAS FORMULACIONES FUE INVESTIGADA PARA SELECCIONAR PREPARACIONES QUE SUMINISTREN PARAMETROS FARMACOCINETICOS EN PLASMA DESEABLES CON ADMINISTRACION PARENTERAL EN CONTRA DE LA ADMINISTRACION ORAL. ADEMAS, SE ESTABLECIO UNA TECNOLOGIA DE EXTRACCION CUANTITATIVA PARA LA CUANTIFICACION DEL BISULFAN EN MUESTRAS DE PLASMA TANTO DESPUES DE LA ADMINISTRACION ORAL COMO PARENTERAL. CUANDO SE ADMINISTRO A ANIMALES EXPERIMENTALES, LA FORMULACION DE BISULFAN PARENTERAL DIO COMO RESULTADO UNA CONCENTRACION MAYOR DE DROGA EN PLASMA Y UNA MAYOR AREA BAJO LA CONCENTRACION EN PLASMA EN CONTRA DE LA CURVA DE TIEMPO EFECTUADA POR LA PREPARACION EN FORMA DE TABLETAS ORALES. LA BIOHABILIDAD MEJORADA DE LA FORMULACION PARENTERAL OPTIMIZA LAS TERAPIAS DE ALTAS DOSIS DE BISULFAN CONTRA ENFERMEDADES MALIGNAS Y MEJORA LA SEGURIDAD DE LAS TERAPIAS.
ES94929116T 1993-09-30 1994-08-30 Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas. Expired - Lifetime ES2153862T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/129,995 US5430057A (en) 1993-09-30 1993-09-30 Parenteral busulfan for treatment of malignant disease

Publications (1)

Publication Number Publication Date
ES2153862T3 true ES2153862T3 (es) 2001-03-16

Family

ID=22442547

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929116T Expired - Lifetime ES2153862T3 (es) 1993-09-30 1994-08-30 Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.

Country Status (13)

Country Link
US (2) US5430057A (es)
EP (1) EP0725637B1 (es)
JP (1) JP3599285B2 (es)
KR (1) KR100371826B1 (es)
AT (1) ATE197670T1 (es)
AU (1) AU694141B2 (es)
CA (1) CA2171738C (es)
DE (1) DE69426334T2 (es)
DK (1) DK0725637T3 (es)
ES (1) ES2153862T3 (es)
GR (1) GR3035447T3 (es)
PT (1) PT725637E (es)
WO (1) WO1995008991A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US7294755B1 (en) 1997-11-14 2007-11-13 Cedars-Sinai Medical Center Genetic modification of male germ cells for generation of transgenic species and genetic therapies
US6734338B1 (en) 1997-11-14 2004-05-11 Cedars-Sinai Medical Center Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
AU761758B2 (en) * 1997-11-14 2003-06-12 Cedars-Sinai Medical Center Transfection and transfer of male germ cells for generation of transgenic species
AU4815699A (en) * 1998-06-18 2000-01-05 Karolinska Innovations Ab Liposomal formulations of busulphan
US7351427B2 (en) * 1998-06-18 2008-04-01 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
US20080131498A1 (en) * 1998-06-18 2008-06-05 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7122640B2 (en) * 2002-06-10 2006-10-17 Phynexus, Inc. Open channel solid phase extraction systems and methods
AU2003247793A1 (en) * 2002-06-26 2004-01-19 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CN1984657B (zh) * 2004-05-05 2010-12-15 细胞基因公司 用于治疗和控制骨髓增生性疾病的包含免疫调节化合物的组合物和使用方法
JP4486994B2 (ja) * 2004-09-15 2010-06-23 サラダックス バイオメディカル インコーポレイテッド ブスルファンイムノアッセイ
WO2008157785A1 (en) * 2007-06-20 2008-12-24 University Of Louisville Research Foundation, Inc. T cell depleting compositions useful for treating cancer
CN102151257B (zh) * 2011-02-17 2015-03-04 四川科瑞德凯华制药有限公司 一种白消安注射剂及其制备方法
PL3238709T3 (pl) 2011-04-28 2021-02-08 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
CN103446045B (zh) * 2012-06-01 2015-08-12 四川科瑞德凯华制药有限公司 一种稳定的白消安注射剂
WO2014089957A1 (zh) * 2012-12-11 2014-06-19 四川科瑞德凯华制药有限公司 一种稳定的白消安注射剂
CN105726467A (zh) * 2014-12-09 2016-07-06 四川科瑞德制药有限公司 一种白消安注射液及其制备方法
CA3062308A1 (en) * 2017-05-03 2018-11-08 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
CN109078005B (zh) * 2018-08-07 2021-11-26 江苏领航生物科技有限公司 一种白消安组合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3109783A1 (de) * 1981-03-13 1982-10-07 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Mit wasser zu einer etwa isotonischen nitroglycerinloesung aufloesbare zubereitung und derartige nitroglycerinloesung
JPS6461429A (en) * 1987-08-29 1989-03-08 Akio Hagiwara Remedy for cancer
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs

Also Published As

Publication number Publication date
EP0725637B1 (en) 2000-11-22
GR3035447T3 (en) 2001-05-31
EP0725637A1 (en) 1996-08-14
KR960704543A (ko) 1996-10-09
ATE197670T1 (de) 2000-12-15
US5559148A (en) 1996-09-24
PT725637E (pt) 2001-06-29
AU7829094A (en) 1995-04-18
WO1995008991A1 (en) 1995-04-06
DE69426334D1 (de) 2000-12-28
AU694141B2 (en) 1998-07-16
JPH09502996A (ja) 1997-03-25
CA2171738C (en) 2002-07-16
US5430057A (en) 1995-07-04
CA2171738A1 (en) 1995-04-06
KR100371826B1 (ko) 2003-05-09
JP3599285B2 (ja) 2004-12-08
DK0725637T3 (da) 2001-03-26
DE69426334T2 (de) 2001-03-29

Similar Documents

Publication Publication Date Title
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
HUP0000558A2 (hu) Aktív D-vitamin analógok alkalmazása prosztatabetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
GB2277873A (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
MY112405A (en) Method of tumer treatment.
EA200300294A1 (ru) Способы лечения связанного с bcl-2 нарушения с использованием bcl-2-антисмысловых олигомеров
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
ATE10738T1 (de) Tetrahydronaphthalin- und indanverbindungen, ihre herstellung und pharmazeutische praeparate.
DE69130063D1 (de) Antivirales arzneimittel enthaltend prostratin
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
PT654267E (pt) Carcinoestaticos para terapia hormonal contendo dienogest como componente eficaz
SE7708622L (sv) 2-bensyl-perhydroazepiner, sett for framstellning derav och lekemedel, innehallande dem
IL101163A (en) Use of flunarizine in the preparation of medicaments for treating neoplastic diseases
ES2067842T3 (es) Uso del factor de necrosis tumoral.
ATE74505T1 (de) Schmerzpraeparat.
PT85076A (en) Method for the treatment of infections disease by administration of tumor necrosis factor-alpha
MX9102181A (es) Iminobenzodiazepina para el tratamiento de desordenes del sueno

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 725637

Country of ref document: ES